Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift From Screening to Prevention
Mainz Biomed Partners With Labor Team W Ag to Launch ColoAlert Colorectal Cancer Screening Test in Switzerland
Mainz Biomed Expands Into Switzerland With Labor Team W
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Maxim Group Initiates Coverage On Mainz Biomed With Buy Rating, Announces Price Target of $14
Mainz Biomed Analyst Ratings
Maxim Starts Mainz Biomed at Buy on CRC Screening Potential
Maxim Group Initiates Mainz Biomed(MYNZ.US) With Buy Rating, Announces Target Price $14
Mainz Biomed Shares Are Trading Higher After the Company Announced Through a Partnership the Launch of Enhanced Coloalert Colorectal Cancer Screening.
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Mainz Biomed Regains Compliance With Nasdaq Listing Requirements
Mainz Biomed N.V. Regains Compliance With Nasdaq Capital Market Listing Requirements
Mainz Biomed Moves Forward With Pivotal CRC Study After Feasibility Trial
Mainz Biomed Launches EAArly DETECT 2 Feasibility Study for Next Generation Colorectal Cancer Test
Mainz Biomed Initiates EAArly DETECT 2 Study To Evaluate Performance Of Colorectal Cancer Test On Advanced Adenomas Over Large Patient Population
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas Over Large Patient Population
Mainz Biomed | 6-K: Report of foreign private issuer (related to financial reporting)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Quest Diagnostics Deal Sends Mainz Higher
Express News | Mainz Biomed NV - Quest to Provide Lab Services for Mainz Biomed's Reconaasense Study